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Invited Mini-review  
Highlights 
- Connexin 43 (Cx43) is an endogenous bone anti-metastatic factor for breast cancer cells 
present in osteocytes. 
- Osteocyte Cx43 proteins function as mechanosensitive hemichannels that release anti-
metastatic molecules like ATP.  
- Bisphosphonate drugs, adjuvants applied in anti-breast cancer treatments, lead to osteocyte 
Cx43-hemichannel opening. 
- Activation of osteocytic hemichannels by mechanical stimulation or bisphosphonate drugs 
suppress breast cancer metastasis in bones. 
- Osteocyte Cx43 hemichannels are endogenous metastatic suppressors that are critical for the 
therapeutic response towards anti-metastasis drugs. 
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Abstract 
Bone metastases of tumor cells are a common and life-threatening feature of a variety of late-stage 
cancers, including breast cancers. However, until now, much less has been known about the intrinsic 
anti-metastatic properties of the bones and how these could be exploited to prevent or treat bone 
metastases. Very recently, native Cx43 hemichannels present in osteocytes have been identified as 
important anti-metastatic signaling complexes by establishing high local extracellular ATP levels. 
Moreover, bisphosphonate drugs, applied as adjuvant therapies in the treatment of breast cancer 
patients and bone diseases, are known to display anti-metastatic properties. Now, it became clear that 
these compounds exert their effects by through osteocyte Cx43 hemichannels, thereby triggering their 
opening and promoting ATP release in the extracellular micro-environment. Hence, endogenous 
osteocyte Cx43 hemichannels emerge as important and promising therapeutic targets for the 
prevention and/or clinical treatment of bone-metastasized breast cancers. 
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Breast cancer metastases to the bone and clinical use of bisphosphonate drugs 
Tumor cells often metastasize to different organs. This is a major life-threatening complication in many 
patients suffering from cancers, including breast cancer, at a late stage [1]. One of the major target 
organs for metastasis of cancer cells is the bone tissue. In the bone, osteocytes arise from osteoblasts 
trapped within the mineralized matrix. Osteocytes dynamically control bone density by impacting the 
function of bone-forming osteoblasts and bone-resorbing osteoclasts (reviewed in [2]). Different 
mechanisms for the occurrence of breast cancer metastases in the bone tissue have been proposed, 
including the production of osteoprotegerin by breast cancer cells and altered Runx2-dependent 
signaling in breast cancer cells [3, 4]. However, much less is known about the intrinsic anti-metastatic 
properties of the bone micro-environment. In addition to this, the relatively well-tolerated 
bisphosphonate drugs applied to treat bone loss and bone diseases, including cancer treatment-
induced bone loss, also reduce the risk of bone metastasis [5, 6]. Bisphosphonates are associated with 
prolonged disease-free survival and with lower breast cancer incidence [7]. A meta-analysis revealed 
a significant benefit of having adjuvant bisphosphonate treatment in early breast cancer patients who 
were in post-menopause [8]. Very recently, a European panel has recommended the use of 
bisphosphonates as an adjuvant in the routine clinical practice for the treatment of early breast 
cancers, e.g. in post-menopause women [9, 10]. Yet, the therapeutic mode of action of 
bisphosphonates on the bone and the molecular targets participating in its physiological effects 
remained not fully understood. 
 
Cx43 proteins function as gap junctions and hemichannels and are present in osteocytes 
A major determinant for the physiological function of osteocytes in bones is the 43-kDa connexin 
protein (Cx43), a 4-transmembrane-domain protein with intracellular N-terminal, loop and C-terminal 
domains and two extracellular loops [11]. The Cx43 protein assembles into hexameric channels that 
can function as “free” hemichannels or “head-to-head”-docked gap junction channels [12, 13], 
establishing intercellular communication and coordination by the passage of low-molecular weight 
molecules (Mw < 1.5 kDa) [11]. Gap junctions allow the direct exchange of intracellular ions, like K+, 
Na+ and Ca2+, signaling molecules, like IP3, and molecules with biological functions, including short 
amino acid peptides and microRNAs. Hemichannels allow the exchange (release or entry) of low Mw 
molecules with the extracellular environment, establishing local, paracrine signaling networks and 
micro-environments through ATP, NAD+, glutamate and prostaglandins [14]. For instance, Cx43 
hemichannels can participate in the release of ATP, thereby eliciting purinergic receptor activation and 
Ca2+ signaling in neighboring cells, detectable as intercellular Ca2+ waves [15, 16]. Physiologically, in 
osteocytes, Cx43 hemichannels are mechanosensitive and become activated by fluid flow and shear 
stress [13]. Therapeutically, part of the bone-protective actions of bisphosphonate drugs could be 
attributed to its ability to trigger Cx43-hemichannel opening, thereby promoting cell survival and 
suppressing apoptosis in osteoblasts and osteocytes (critically reviewed in [17]). The presence of 
functional Cx43 hemichannels in osteoblasts and osteocytes was critical for the activation of cell 
survival signaling pathways, like Src and ERK, in response to bisphosphonate drugs and to protect 
against in vivo bone loss induced by glucocorticoids [18-20].  Very recently, the negative impact of 
glucocorticoids on osteocytes has been linked to a prominent decrease in Cx43-protein levels [21]. This 
is due to glucocorticoid-induced inhibition of Akt-mTORC1 signaling, which leads to an upregulation of 
autophagy [22], a major turn-over pathway for Cx43 gap junctions and hemichannels [22-25]. Indeed, 
independent studies previously showed that while high doses of glucocorticoids could induce 
apoptosis in osteocytes, low doses of glucocorticoids induced autophagy in osteocytes [26], which will 
negatively impact Cx43-protein levels. 
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Cx43 and its role in oncogenesis and cancer hall-marks 
Cx43 in tumor cells 
Cx43 expression has been linked to different tumor biological aspects for a variety of cancers, including 
breast cancers [27, 28]. This involves channel-dependent functions by promoting gap junctional and/or 
hemichannel-mediated intercellular communication and channel-independent functions by 
sequestering putative gene regulators and by providing Cx43-protein fragments that can translocate 
to the nucleus and regulate gene transcription [29]. Most insights about the role of Cx43 in the 
oncogenesis of cancer cells have been obtained on Cx43 channels present in tumor cells, where they 
impact different “hall-marks of cancer”. In different cancer cell types, including glioma and breast 
cancers, Cx43 expression inhibits cell-cycle progression tumor growth, proliferation and migration, 
although Cx43 can also enhance cell migration and motility [29-31]. This dichotomous role for Cx43 is 
also reflected in its altered expression in different stages of tumor formation and spreading. Indeed, 
Cx43 expression is often lost during the early stages of the formation of primary breast tumors, while 
Cx43 expression is upregulated during metastasis and secondary tumor formation [28]. As such, Cx43 
functions as a tumor suppressor in primary breast tumors, while it can act as either tumor suppressor 
or tumor promoter in advanced breast cancers at later stages dependent on the context [32].  
Moreover, the effects of Cx43 expression on tumor cells might be dependent on its localization. For 
instance, in prostate LNCAP cancer cells, re-expressed Cx43 occurs at the cell membrane and increases 
tumor growth and invasion, while in PC-3 prostate cancer cells, re-expressed Cx43 occurs in the cytosol 
and prevents tumor growth and invasion. Also, in prostate cancer cell lines, Cx43 expression appeared 
to positively correlate with their increasing metastatic potential [33]. Knocking down Cx43 suppressed 
the metastatic properties of these cancer cells, while it did not impact their cell growth. Cx43 
expression can also impact cell death and survival, processes often dysregulated in cancer cells. Cx43 
gap junctions and hemichannels have been implicated in the spreading of cell death and survival 
factors, e.g. by facilitating the spreading of signaling molecules that become released upon 
mitochondrial outer membrane permeabilization, an important onset point for apoptosis [34, 35]. 
Cx43 in target tissues for hosting metastasized tumors 
Besides the extensively studied role of Cx43 in the tumor cells, including breast cancers (recently 
thoroughly reviewed in [28]), Cx43 from host tissues also controls the eventual seeding and growth of 
the metastases and secondary tumors. Cx43 present in the host tissues promotes cancer cell migration 
and tissue invasion by forming hetero-cellular gap junctions between Cx43 from the tumor cells and 
Cx43 from the host tissue [30]. Via these hetero-cellular gap junctions, glioma cells can transfer a 
specific subset of microRNAs to astrocytes, like miR-5096, which contributed to the pro-invasive effect 
[36]. The pro-invasive role of Cx43 has recently been observed in vivo in the peri-tumoral region 
between glioma cells and astrocytes [37]. Absence of Cx43 in the tumors or in the astrocytic host 
environment attenuates invasion in the astrocyte environment. Very recently, further mechanistic 
insights on the interplay between metastasized tumor cells and astrocytes have been obtained [38]. 
New Cx43 gap junctions are formed between tumor cells and astrocytes through protocadherin 7, 
which is expressed in astrocytes and several cancer cells, including the ones originating from breast 
and lung tissues.  These hetero-cellular Cx43 gap junctions between cancer cells and astrocytes provide 
an exchange pathway for second messenger cyclic GMP-AMP (cGAMP) signaling molecules from 
cancer cells towards astrocytes. In astrocytes, cGAMP initiate “stimulator of interferon genes” (STING) 
signaling, an innate immune response pathway activated upon double-standed DNA appearance in the 
cytosol [39]. STING activation results in the production and release of inflammatory cytokines 
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interferon-α and tumor necrosis factor from astrocytes. As a consequence, tumor cells are influenced 
by these paracrine factors, activating STAT1 and NK-B pathways, which favor tumor growth and 
promote chemoresistance [38]. However, besides the pro-metastatic roles of native Cx43, like in 
astrocytes, Cx43 expression in other host tissues like the lungs can also counteract tumor metastasis 
and cancer growth in these tissues, as lack of proper Cx43 expression in the host organism facilitated 
the occurrence of mammary gland tumor metastasis to the lungs [40].  
However, until now, the impact of Cx43 channels on tumor metastasis in the bone and their role in the 
anti-metastatic properties of bisphosphonate drugs were poorly understood. In particular, most 
studies describing a role for Cx43 in metastasis and invasion reported its contribution as gap junctional 
channels, but their role as hemichannels in these processes remained largely unexplored. This was 
largely due to the fact that Cx43 knockout approaches will obviously impact both Cx43 gap junctions 
and hemichannels, while selective Cx43 gap junction inhibitors remained not without side effects. Yet, 
recent insights in the distinct regulation of Cx43 gap junctions versus hemichannels by intramolecular 
loop/tail interactions have opened novel opportunities to design mutant channels and peptide tools 
that could abolish gap junctional channel activity while retaining hemichannel activity and vice versa 
[14, 41-46]. These insights, tools and experimental approaches now provide unprecedented 
opportunities to unravel (patho)physiological functions of Cx43 as gap junctional channels versus 
hemichannels [43]. 
 
The role of osteocyte Cx43 hemichannels in establishing an endogenous anti-metastatic bone micro-
environment and in the therapeutic response towards anti-metastatic drugs  
Recent studies from the Jiang team revealed that endogenous Cx43 hemichannels present in 
osteocytes function as novel anti-neoplastic factors preventing bone metastasis of breast cancer cells 
[47, 48] (see Fig. 1 for the model). Medium collected from osteocytes exposed to bisphosphonate 
drugs, like alendronate, inhibited the migration of breast cancer cells and anchorage-independent 
growth. This migration was dependent on ATP released from osteocytes and on purinergic P2X7 
receptor-mediated signaling in the breast cancer cells. Indeed, ATP-degrading enzymes or P2X7 
antagonist alleviated the inhibition of breast cancer cell migration, while P2X7 agonists by themselves 
were able to inhibit breast cancer cell migration. ATP by itself had a biphasic effect on the migration 
by breast cancer cells with low concentration causing inhibition of migration while high concentration 
promoting migration [47]. This effect could be attributed to the metabolism of ATP, since non-
hydrolysable ATP only inhibited migration, while adenosine, a metabolic product of ATP, only 
promoted migration. In follow-up work, the authors showed that bisphosphonate drugs inhibit breast 
cancer cell migration and anchorage-independent tumor growth. These anti-metastatic properties of 
bisphosphonates were attributed to their ability to trigger ATP release from osteocytes by opening 
Cx43 hemichannels, since an anti-Cx43 antibody directed against the extracellular loop that inhibits 
Cx43-hemichannel opening abolished the anti-migration effect [48]. Interestingly, osteoblast cells 
expressing Cx43 did not release ATP in response to bisphosphonate drugs and the medium collected 
of these cells did not impact breast cancer cell migration, indicating a critical role for Cx43 
hemichannels present in osteocytes. Also, not only alendronate but also zoledronic acid, an FDA-
approved drug for the treatment of bone metastases, could trigger Cx43-hemichannel opening from 
osteocytes and suppress cell growth and migration of breast cancer cells, suggesting that activation of 
Cx43 hemichannels may be a common feature of different bisphosphonate drugs. Moreover, not only 
pharmacological tools but also physiological conditions like mechanical stimulation of osteocytes by 
fluid flow shear stress also triggered Cx43-hemichannel-mediated ATP release and the medium of 
osteocytes exposed to a physiological form of mechanical stimulation was able to inhibit breast cancer 
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cell migration. This indicates that also physiological opening of Cx43 hemichannels present in 
osteocytes can prevent metastasis. This is underpinned by in vivo experiments using an osteocyte-
specific Cx43-knockout mouse model. In comparison to wild-type mouse, breast cancer cells grew 
much faster in the osteocyte-specific Cx43 knockout mouse model. Since the Cx43 protein serves as a 
building block for both gap junctions and hemichannels, a Cx43 knockout cannot identify whether the 
anti-metastatic properties are due to Cx43’s function as gap junctions or hemichannels. Therefore, the 
authors elegantly used two mouse models, one in which osteocytes were lacking functional Cx43 gap 
junctions but were expressing functional Cx43 hemichannels (Cx43R76W) and one in which osteocytes 
were lacking functional Cx43 gap junctions and hemichannels (Cx43Δ130-136) (see Fig. 2 for the Cx43 
mutants used and their functional outcome). Importantly, tumor growth in the bones was significantly 
accelerated in the Cx43Δ130-136 mouse model compared to the wild-type mice or Cx43R76W mice. 
Furthermore, treatment of the mice with bisphosphonates drugs suppressed tumor growth in the 
bones of wild-type mice or Cx43R76W mice, but its anti-tumor properties were abolished in mice 
expressing Cx43Δ130-136. Of note, also mechanical loading, a physiological stimulus for the opening of 
osteocytic Cx43 hemichannels, inhibited the migration of breast cancer cells. This is important, given 
the beneficial effects of physical exercise, which likely is associated with increased mechanical 
stimulation of osteocytes due to fluid flow, towards reduced tumor growth and metastasis. Thus, these 
studies now identified (i) Cx43 hemichannels present in osteocytes as novel tumor suppressors 
counteracting bone metastasis and tumor growth and (ii) the pharmacological targets of 
bisphosphonate drugs used in the clinic to treat bone metastasis. The mechanism of action of these 
drugs involves the opening of Cx43 hemichannels from osteocytes. Thus, this study further underpins 
the emerging physiological functions of Cx43 hemichannels as ATP-release pathway in a variety of cell 
systems, tissues and organs. Here, Cx43 hemichannels in the bone are shown to possess a “self-
protective” action that counteracts the metastatic behavior of breast cancer cells, avoiding bone tissue 
colonization by these cancer cells.  
 
Remaining questions and future directions 
However, this study also raises a number of fundamental questions and challenges for the therapeutic 
applications of these concepts for the benefit of human health in anti-cancer treatments. First of all, it 
will be interesting to establish whether the anti-metastatic potential of osteocyte Cx43 hemichannels 
can be expanded to other tumors besides breast cancers, as obviously many tumors can metastasize 
towards the bones. Second, other sites of metastasis include the lungs and the brain, but the 
contribution and/or potential of hemichannels established by Cx43 (or other Cx isoforms) to 
counteract metastases in these tissues remains unknown. Also, at the level of the mechanism of action 
of bisphosphonate drugs towards (specific?) activation of osteocytic Cx43 hemichannels further work 
is needed. For instance, it is not clear how bisphosphonate drugs result in the opening of Cx43 
hemichannels from osteocytes. The signaling pathways involved ought to be elucidated. Interestingly, 
it appears that the bisphosphonate drugs are selectively acting on Cx43 hemichannels present in 
osteocytes, since osteoblasts expressing Cx43 hemichannels do not release ATP upon bisphosphonate 
drug exposure, although other studies convincingly challenge this concept (reviewed in [17]). Thus, the 
difference between osteoblasts and osteocytes in responsiveness to bisphosphonate drugs will be an 
interesting avenue to explore. Importantly, work from Morelli and team using Cx43-expressing and 
Cx43-deficient cells argued against a direct binding of alendronate to Cx43 hemichannels and also 
excluded Cx43 hemichannels as an uptake route for bisphosphonate drugs in osteocytes/osteoblasts 
[49]. Also, in this work, the anti-apoptotic effects of bisphosphonate drugs were dependent on Cx43 
hemichannels, while their proliferative effects on osteoblasts were independent of the presence of 
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Cx43 hemichannels [49].   
In addition, the impact of bisphosphonate drugs on Cx43 hemichannels present in other cell types or 
tissues, including astrocytes or cardiomyocytes, ought to be scrutinized, as this could lead to serious 
adverse side-effects. Furthermore, further long-term studies on osteocytes are needed to show 
whether bisphosphonate could impact the viability of osteocytes, since excessive Cx43-hemichannel 
opening could lead to a collapse of ionic, metabolic and energetic gradients essential for cell survival. 
Also, at the level of the breast cancer cells, the anti- and pro-neoplastic signaling pathways and 
processes activated in response to ATP-mediated P2X7 receptor stimulation and adenosine-mediated 
adenosine receptor stimulation, respectively, ought to be further characterized. 
At the therapeutic level, it will be important to determine whether in vivo treatments with 
bisphosphonate drugs are effective in inhibiting tumor growth in bones, definitely in long-term 
settings. Furthermore, ATP released from osteocytes was shown to display biphasic effects on breast 
cancer cell migration due to the stimulatory effects of adenosine, a metabolic product of ATP, on this 
process [50]. As bisphosphonate drugs exert part of their anti-metastatic effects by opening osteocyte 
Cx43 hemichannels and raising extracellular ATP in the tumor micro-environment, the appearance of 
adenosine in the tumor micro-environment, which promotes tumor growth, migration and metastasis 
[50] and which leads to impaired immune-surveillance [51], may hamper their long-term therapeutic 
applicability. Although different processes contribute to the accumulation of adenosine in the tumor 
micro-environment, the presence of ectonucleotidases like CD39 and CD73 at the surface of breast 
cancer cells or secreted via exosomes is the main mechanism for producing extracellular adenosine by 
catalyzing the following conversions: ATP  ADP  AMP  adenosine [52]. Hence, combination 
strategies with inhibitors of the ectonucleotidases CD39 and CD73 or antagonists of adenosine-
mediated signaling pathways could overcome the adverse effects of the ATP-metabolic product 
adenosine. In addition, these CD73 and A2A inhibitors will also help to counteract tumor metastases by 
boosting host anti-tumor immune responses. For instance, blockade of A2A receptors suppressed 
metastases by promoting the maturation and function of natural killer cells [53]. Also, an inhibitory 
anti-CD73 monoclonal antibody inhibits tumor growth and metastases in immune-competent but not 
in immune-deficient mice [54]. 
Another important aspect to consider is the endogenous Cx43 protein-levels in the bone of cancer 
patients. Since bisphosphonate drugs exert their function by opening Cx43 hemichannels in 
osteocytes, the Cx43-expression levels and its occurrence as hemichannels in osteocytes will be crucial 
for the therapeutic effect of these drugs. In particular, it should be examined whether Cx43 levels in 
osteocytes remain sufficiently high in cancer patients to establish sufficient Cx43 hemichannels and 
thus to sufficiently raise ATP levels in the osteocyte/tumor micro-environment. Thus, tools that favor 
Cx43-hemichannel opening in response to activating stimuli may boost the anti-metastatic properties 
of bisphosphonate drugs. Such tools have recently become available based on insights in the molecular 
determinants underlying Cx43-hemichannel activation. It was discovered that intramolecular 
interactions between in the cytoplasmic loop of Cx43 and the last 10 amino acids of the Cx43 C-
terminal tail not only control Cx43 gap junction activity but also Cx43-hemichannel activity. Strikingly, 
while such interactions close Cx43 gap junctions, they are critical to render Cx43 hemichannels in a 
“ready to open” state [44]. Thus, cell-permeable peptides representing parts of the cytoplasmic loop, 
like TAT-L2, Gap19 or TAT-Gap19, inhibit Cx43 hemichannel opening in a variety of cellular systems in 
response to physiological stimuli like moderate [Ca2+]cyt increases [45, 46], extracellular Ca2+ buffer [45, 
46, 55, 56], mechanical stimulation [45] or depolarization [44], while favoring Cx43 gap junctional 
channel opening [57]. Moreover, these peptide tools can also limit excessive Cx43 hemichannel 
openings in response to pathophysiological stimuli like ischemia reperfusion cardiac systems [46]. This 
suppresses cell damage to these tissues, thereby maintaining their physiological functions [41, 42, 58]. 
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In contrast, cell-permeable peptides representing the last 10 amino acids, like TAT-CT10, can prevent 
the closure of Cx43 hemichannels in conditions that activate the actomyosin contractility like high 
[Ca2+]cyt [45, 59]. As such, TAT-CT10 peptide may promote the effectiveness of bisphosphonate drugs 
by favoring the opening of endogenous osteocyte Cx43 hemichannels. The ability of these tools to 
promote endogenous Cx43 hemichannel activity has recently been established in nodose ganglion 
sensory neurons, thereby increasing their excitability [60]. Interestingly, a related peptide, ACT1, an 
antennapedia-coupled CT10 peptide, which promotes gap junctional assembly by interfering with 
Cx43/ZO-1 complexes and sustains intercellular coupling [61], enhanced the activity of tamoxifen and 
lapatinib in breast cancers [62]. Thus, beyond their beneficial role in wound healing [63-65] and 
maintaining gap junction coupling in cardiac injury paradigms [63],  CT10-based tools might be very 
effective adjuvant molecules in anti-cancer strategies in two ways: (i) by promoting Cx43 gap junctional 
coupling between breast cancer cells favoring sensitivity to targeted inhibitors, e.g. through 
`bystander` effects [34, 35] and (ii) by enhancing endogenous Cx43-hemichannel activity from 
osteocytes boosting the effects of bisphosphonate drugs to establish an ATP-rich, anti-metastatic 
micro-environment. 
Finally, Cx43-hemichannel opening has been associated with a plethora of pathophysiological 
conditions, including ischemia/reperfusion in the brain and heart, inflammatory conditions, 
neurodegenerative conditions like amyloid beta accumulation [58, 66, 67]. As such, inhibition of Cx43 
hemichannel opening has been proposed as a promising therapeutic application for these conditions 
[46, 58]. These findings together with advances in understanding the mechanisms that control Cx43-
hemichannel activity have spurred the development of selective Cx43 hemichannel inhibitors that do 
not negatively impact Cx43 gap junction activity [41, 42, 44, 45]. Yet, the timeframe of treatments with 
Cx43-hemichannel inhibitors will be an important aspect to consider. Indeed, given the inherent tumor 
suppressive and anti-metastatic role of osteocytic Cx43 hemichannels, long-term treatments with 
Cx43-hemichannel inhibitors might adversely impact the risk for developing cancer metastasis to the 
bone, e.g. in patients with breast cancer. However, the application of Cx43-hemichannel inhibitors to 
limit cell damage in response to ischemia/reperfusion is anticipated to be a relatively short-term 
intervention, thus likely avoiding a negative impact on the anti-metastatic properties of osteocytic 
Cx43 hemichannels. 
 
Conclusions 
Overall, over the years, it has become clear that Cx43-hemichannel openings are not only associated 
with pathological conditions, but are also involved in important physiological signaling processes by 
releasing molecules like ATP and glutamate. Now, for the first time, Cx43-hemichannel opening is 
associated with antagonizing a pathological condition, namely cancer cell metastasis in the bones, by 
mediating local ATP release from osteocytes in response to physiological stimuli (mechanical 
stimulation) and therapeutics (bisphosphonates). Hence, osteocytic Cx43 hemichannels act as native 
and endogenous suppressors of breast cancer metastases in the bone and serve a crucial role in the 
therapeutic response towards bisphosphonate-based drugs, already clinically used as chemotherapy 
adjuvants for treating bone metastases. These findings open exciting avenues for further fundamental 
and translational research, including the therapeutic application of these concepts in the clinical 
treatment of breast cancer patients to prevent or cure bone metastasis. 
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Figure 1. Osteocytic Cx43 hemichannels as anti-metastatic factors in the bone. Cx43 is important for 
the function and viability of osteocytes by acting as mechanosensitive hemichannels mediating the 
release of signaling molecules, including ATP. Recent work from the team of Jiang revealed that Cx43 
hemichannels function as endogenous suppressors of breast cancer cell metastasis in the bone and 
are crucial for the therapeutic response towards bisphosphonate drugs, compounds used in the clinic 
as adjuvant for the treatment of early breast cancers. Opening of osteocyte hemichannels, in response 
to physiological stimuli like mechanical loading or to pharmacological stimuli like bisphosphonate 
drugs (structure of alendronate is shown; taken from 
http://images.ddccdn.com/img/mol/DB00630.mol.jpg), result in the release of ATP, a signaling 
molecule exerting anti-neoplastic function on breast cancer cells by acting on the purinergic P2X7 
receptors. Of importance, adenosine a metabolic product of ATP exert pro-neoplastic action on breast 
cancer cells by acting on the adenosine receptor A2A. Thus, strategies that counteract ATP degradation 
(e.g. by inhibiting the ectonucleotidases CD39 and CD73) and thus prevent adenosine accumulation in 
the tumor micro-environment may be needed to further to maximize the therapeutic effects of 
bisphosphonate drugs in the prevention and/or treatment of breast cancer metastasis. 
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Figure 2. Overview of the osteocytic Cx43 mutants and Cx43-targeting tools like the E2 antibody used 
by Jiang and co-workers [48] and their functional outcome in terms of gap junctions, hemichannels 
and anti-metastatic potential in response to bisphosphonate drugs. A, A schematic illustration of the 
human Cx43 protein sequence (Protein Accession Number used: P17302) using the Protter protein-
visualization tool (http://wlab.ethz.ch/protter/start/; [68]), which represents one building block of the 
hexameric hemichannel and the head-to-head-docked hemichannel that establish a gap junction 
channel. The location of the relevant mutations and deletions used by Jiang and co-workers are 
highlighted in a red box, i.e. Cx43R76W and Cx43130-136. The E2 antibody (E2-Ab), targeting the second 
extracellular loop, is also depicted. B, A table representing the functional outcome  and impact on the 
anti-metastatic properties of osteocytes and bone micro-environment of wild-type Cx43, Cx43 
mutants, selectively expressed in osteocytes, and the E2 antibody targeting Cx43. Osteocytes 
expressing Cx43, which establish functional gap junctions and hemichannels, suppress breast cancer 
metastasis to the bone in response to physiological stimuli and bisphosphonate anti-metastatic drugs. 
Osteocytes expressing Cx43R76W, which can form functional hemichannels but not functional gap 
junctions, remains capable of counteracting bone metastases. This excludes that Cx43 gap junctions 
are required for the anti-metastatic properties of bisphosphonates. Osteocytes expressing Cx43130-136, 
which can neither form functional gap junctions nor functional hemichannels, lost their ability to 
suppress bone metastases. Selective inhibition of Cx43 hemichannels using the E2 antibody (E2-Ab), 
thereby maintaining gap junction function, is able to neutralize the anti-metastatic properties of 
osteocytes upon exposure to bisphosphonate drugs in in vitro experiments 
